Antimicrob Agents Chemother
-
Publication Venue For
-
Pharmacokinetics of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) in a Phase 1, Open-Label Study of Healthy Adults..
66:e0093622.
2022
-
Safety of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) in a Phase I, Open-Label Study in Healthy Adult Volunteers..
66:e0093522.
2022
-
Antibiotic Prophylaxis for Megaprosthetic Reconstructions: Drug and Dosing May Matter More than Duration..
66:e0014022.
2022
-
Antiplatelet Therapy in Staphylococcus aureus Bacteremia: No Time Like the Past?.
66:e0036522.
2022
-
Safety of Inhaled Amphotericin B Lipid Complex as Antifungal Prophylaxis in Lung Transplant Recipients..
66:e0028322.
2022
-
First-in-Human Clinical Trial to Assess the Safety, Tolerability and Pharmacokinetics of Single Doses of NTM-1633, a Novel Mixture of Monoclonal Antibodies against Botulinum Toxin E..
66:e0173221.
2022
-
Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models..
66:e0239821.
2022
-
Pharmacodynamics of Meropenem and Tobramycin for Neonatal Meningoencephalitis: Novel Approaches to Facilitate the Development of New Agents to Address the Challenge of Antimicrobial Resistance..
66:e0218121.
2022
-
Adaptive Responses of Pseudomonas aeruginosa to Treatment with Antibiotics..
66:e0087821.
2022
-
Population Pharmacokinetics and Pharmacodynamics of Itraconazole for Disseminated Infection Caused by Talaromyces marneffei..
65:e0063621.
2021
-
Of Rats and Men: a Translational Model To Understand Vancomycin Pharmacokinetic/Toxicodynamic Relationships..
65:e0106021.
2021
-
External Evaluation of Two Pediatric Population Pharmacokinetics Models of Oral Trimethoprim and Sulfamethoxazole..
65:e0214920.
2021
-
Safety, Tolerability, and Pharmacokinetics of NTM-1632, a Novel Mixture of Three Monoclonal Antibodies against Botulinum Toxin B..
65:e0232920.
2021
-
Variability of Hydroxy-Itraconazole in Relation to Itraconazole Bloodstream Concentrations..
65.
2021
-
Evidence-Based Guidelines Should Be Used To Inform COVID-19 Management..
65.
2021
-
Pharmacokinetic and Pharmacodynamic Profiling of Minocycline for Injection following a Single Infusion in Critically Ill Adults in a Phase IV Open-Label Multicenter Study (ACUMIN)..
65.
2021
-
Optimization of a Noncanonical Anti-infective: Interrogation of the Target Binding Pocket for a Small-Molecule Inhibitor of Escherichia coli Polysaccharide Capsule Expression..
65.
2020
-
Early Oral Antibiotic Switch for Staphylococcus aureus Bacteremia: Many Are Called, but Few Are Chosen..
64.
2020
-
Scope and Predictive Genetic/Phenotypic Signatures of Bicarbonate (NaHCO3) Responsiveness and β-Lactam Sensitization in Methicillin-Resistant Staphylococcus aureus..
64.
2020
-
Phase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation..
64.
2020
-
Relationship between Vancomycin MIC and Virulence Gene Expression in Clonal Complexes of Methicillin-Susceptible Staphylococcus aureus Strains Isolated from Left-Sided Endocarditis..
64.
2020
-
A Systematic Review and Meta-analysis of the Prevalence of Community-Onset Bloodstream Infections among Hospitalized Patients in Africa and Asia..
64.
2019
-
Amphotericin B Penetrates into the Central Nervous System Through Focal Disruption of the Blood Brain Barrier in Experimental Hematogenous Candida Meningoencephalitis..
63.
2019
-
Population Pharmacokinetics of Doxycycline in Children..
63.
2019
-
Pharmacodynamics of Isavuconazole in a Rabbit Model of Cryptococcal Meningoencephalitis..
63.
2019
-
Rifampin Pharmacokinetics and Safety in Preterm and Term Infants..
63.
2019
-
Reply to Frange and Leruez-Ville, "Caution Is Required before Recommending Wide Use of Letermovir as Salvage Therapy for Cytomegalovirus Diseases"..
63.
2019
-
Use of Letermovir as Salvage Therapy for Drug-Resistant Cytomegalovirus Retinitis..
63.
2019
-
Population Pharmacodynamics of Amphotericin B Deoxycholate for Disseminated Infection Caused by Talaromyces marneffei..
63.
2019
-
In Vitro and In Vivo Assessment of FK506 Analogs as Novel Antifungal Drug Candidates..
62.
2018
-
External Evaluation of a Gentamicin Infant Population Pharmacokinetic Model Using Data from a National Electronic Health Record Database..
62.
2018
-
In Vitro and In Vivo Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus..
62.
2018
-
Population Pharmacokinetics and Safety of Solithromycin following Intravenous and Oral Administration in Infants, Children, and Adolescents..
62.
2018
-
A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study)..
62.
2018
-
Identification of Hsp90 Inhibitors with Anti-Plasmodium Activity..
62.
2018
-
Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies..
62.
2018
-
Population Pharmacokinetics of Trimethoprim-Sulfamethoxazole in Infants and Children..
62.
2018
-
Reduced Chlorhexidine and Daptomycin Susceptibility in Vancomycin-Resistant Enterococcus faecium after Serial Chlorhexidine Exposure..
62.
2018
-
External Evaluation of Two Fluconazole Infant Population Pharmacokinetic Models..
61.
2017
-
Antifungal Activity of SCY-078 and Standard Antifungal Agents against 178 Clinical Isolates of Resistant and Susceptible Candida Species..
61.
2017
-
N-Acylated Derivatives of Sulfamethoxazole Block Chlamydia Fatty Acid Synthesis and Interact with FabF..
61.
2017
-
Genomic Analysis of Multidrug-Resistant Escherichia coli from North Carolina Community Hospitals: Ongoing Circulation of CTX-M-Producing ST131-H30Rx and ST131-H30R1 Strains..
61.
2017
-
Experimental Models of Short Courses of Liposomal Amphotericin B for Induction Therapy for Cryptococcal Meningitis..
61.
2017
-
Results from a 13-Year Prospective Cohort Study Show Increased Mortality Associated with Bloodstream Infections Caused by Pseudomonas aeruginosa Compared to Other Bacteria..
61.
2017
-
Streptococcus mitis and S. oralis Lack a Requirement for CdsA, the Enzyme Required for Synthesis of Major Membrane Phospholipids in Bacteria..
61.
2017
-
Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?.
61.
2017
-
Pharmacokinetics of Clindamycin in Obese and Nonobese Children..
61.
2017
-
Fungal CYP51 Inhibitors VT-1161 and VT-1129 Exhibit Strong In Vitro Activity against Candida glabrata and C. krusei Isolates Clinically Resistant to Azole and Echinocandin Antifungal Compounds..
61.
2017
-
Increased Costs Associated with Bloodstream Infections Caused by Multidrug-Resistant Gram-Negative Bacteria Are Due Primarily to Patients with Hospital-Acquired Infections..
61.
2017
-
Antistaphylococcal β-Lactams versus Vancomycin for Treatment of Infective Endocarditis Due to Methicillin-Susceptible Coagulase-Negative Staphylococci: a Prospective Cohort Study from the International Collaboration on Endocarditis..
60:6341-6349.
2016
-
Population Pharmacokinetics of Fluconazole in Premature Infants with Birth Weights Less than 750 Grams..
60:5539-5545.
2016
-
Clindamycin Pharmacokinetics and Safety in Preterm and Term Infants..
60:2888-2894.
2016
-
Solithromycin Pharmacokinetics in Plasma and Dried Blood Spots and Safety in Adolescents..
60:2572-2576.
2016
-
Telavancin for Acute Bacterial Skin and Skin Structure Infections, a Post Hoc Analysis of the Phase 3 ATLAS Trials in Light of the 2013 FDA Guidance..
59:6170-6174.
2015
-
Calcium-Mediated Induction of Paradoxical Growth following Caspofungin Treatment Is Associated with Calcineurin Activation and Phosphorylation in Aspergillus fumigatus..
59:4946-4955.
2015
-
Hsp70 and the Cochaperone StiA (Hop) Orchestrate Hsp90-Mediated Caspofungin Tolerance in Aspergillus fumigatus..
59:4727-4733.
2015
-
Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates..
59:4308-4311.
2015
-
Fluconazole population pharmacokinetics and dosing for prevention and treatment of invasive Candidiasis in children supported with extracorporeal membrane oxygenation..
59:3935-3943.
2015
-
Candida infective endocarditis: an observational cohort study with a focus on therapy..
59:2365-2373.
2015
-
Depot medroxyprogesterone acetate in combination with a twice-daily lopinavir-ritonavir-based regimen in HIV-infected women showed effective contraception and a lack of clinically significant interactions, with good safety and tolerability: results of the ACTG 5283 study..
59:2094-2101.
2015
-
Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections..
59:864-871.
2015
-
Population pharmacokinetics of micafungin and its metabolites M1 and M5 in children and adolescents..
59:905-913.
2015
-
Safety, tolerability, and efficacy of GSK1322322 in the treatment of acute bacterial skin and skin structure infections..
58:6518-6527.
2014
-
Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia..
58:5758-5765.
2014
-
Surveillance of carbapenem-resistant Klebsiella pneumoniae: tracking molecular epidemiology and outcomes through a regional network..
58:4035-4041.
2014
-
Characterization of the population pharmacokinetics of ampicillin in neonates using an opportunistic study design..
58:3013-3020.
2014
-
Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival..
58:3581.
2014
-
Developmental pharmacokinetics of piperacillin and tazobactam using plasma and dried blood spots from infants..
58:2856-2865.
2014
-
Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin griffithsin in two laboratory rodent models..
58:120-127.
2014
-
Identification of a key lysine residue in heat shock protein 90 required for azole and echinocandin resistance in Aspergillus fumigatus..
58:1889-1896.
2014
-
Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival..
58:2030-2037.
2014
-
Widespread dissemination of CTX-M-15 genotype extended-spectrum-β-lactamase-producing enterobacteriaceae among patients presenting to community hospitals in the southeastern United States..
58:1200-1202.
2014
-
Genotypic analysis of the V3 region of HIV from virologic nonresponders to maraviroc-containing regimens reveals distinct patterns of failure..
57:6122-6130.
2013
-
High-dose daptomycin therapy for left-sided infective endocarditis: a prospective study from the international collaboration on endocarditis..
57:6213-6222.
2013
-
Approaches to antifungal therapies and their effectiveness among patients with cryptococcosis..
57:2485-2495.
2013
-
Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints..
57:2793-2800.
2013
-
Real-time treatment guidelines: considerations during the Exserohilum rostratum outbreak in the United States..
57:1573-1576.
2013
-
Growth inhibition of pathogenic bacteria by sulfonylurea herbicides..
57:1513-1517.
2013
-
Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole..
56:5898-5906.
2012
-
TD-1792 versus vancomycin for treatment of complicated skin and skin structure infections..
56:5476-5483.
2012
-
Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine..
56:3107-3113.
2012
-
Population pharmacokinetics of metronidazole evaluated using scavenged samples from preterm infants..
56:1828-1837.
2012
-
Anidulafungin for neonatal hematogenous Candida meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approach..
56:708-714.
2012
-
Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults..
55:5780-5789.
2011
-
Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults..
55:5770-5779.
2011
-
Predictors of agr dysfunction in methicillin-resistant Staphylococcus aureus (MRSA) isolates among patients with MRSA bloodstream infections..
55:5433-5437.
2011
-
Analysis of low-frequency mutations associated with drug resistance to raltegravir before antiretroviral treatment..
55:1114-1119.
2011
-
Combinatorial phenotypic signatures distinguish persistent from resolving methicillin-resistant Staphylococcus aureus bacteremia isolates..
55:575-582.
2011
-
Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections..
55:583-592.
2011
-
Dissemination of an Enterococcus Inc18-Like vanA plasmid associated with vancomycin-resistant Staphylococcus aureus..
54:4314-4320.
2010
-
Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children..
54:4116-4123.
2010
-
Population pharmacokinetics of micafungin in neonates and young infants..
54:2633-2637.
2010
-
Determination of an inoculum effect with various cephalosporins among clinical isolates of methicillin-susceptible Staphylococcus aureus..
54:2206-2208.
2010
-
Transcriptional regulation of chitin synthases by calcineurin controls paradoxical growth of Aspergillus fumigatus in response to caspofungin..
54:1555-1563.
2010
-
Inoculum effect with cefazolin among clinical isolates of methicillin-susceptible Staphylococcus aureus: frequency and possible cause of cefazolin treatment failure..
53:3437-3441.
2009
-
Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers..
53:2960-2964.
2009
-
Antibiotic resistance in urinary isolates of Escherichia coli from college women with urinary tract infections..
53:1285-1286.
2009
-
Virologic failure in first-line human immunodeficiency virus therapy with a CCR5 entry inhibitor, aplaviroc, plus a fixed-dose combination of lamivudine-zidovudine: nucleoside reverse transcriptase inhibitor resistance regardless of envelope tropism..
53:1116-1123.
2009
-
Virologic failure in therapy-naive subjects on aplaviroc plus lopinavir-ritonavir: detection of aplaviroc resistance requires clonal analysis of envelope..
53:1124-1131.
2009
-
Differential effects of inhibiting chitin and 1,3-{beta}-D-glucan synthesis in ras and calcineurin mutants of Aspergillus fumigatus..
53:476-482.
2009
-
Population pharmacokinetics of fluconazole in young infants..
52:4043-4049.
2008
-
Rationale for reading fluconazole MICs at 24 hours rather than 48 hours when testing Candida spp. by the CLSI M27-A2 standard method..
52:4175-4177.
2008
-
Microbiological and genotypic analysis of methicillin-resistant Staphylococcus aureus bacteremia..
52:3441-3443.
2008
-
Inhibitory effect of PRO 2000, a candidate microbicide, on dendritic cell-mediated human immunodeficiency virus transfer..
52:1751-1758.
2008
-
Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir..
52:1663-1669.
2008